Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Open accessThe DOI matches its Crossref record; 33 of the 36 references it cites were found in a registry or an index.
Abstract
Background Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU). It is unclear whether this occurs because such tumours have better prognosis or they are more sensitive to 5-FU treatment.Patients and methods Associations between TS, DPD and TP levels, determined by tissue microarrays and immunohistochemistry, and survival was evaluated in 945 CRC patients according to treatment status.Results Low TS and DPD expression associated with worse prognosis in stage II [hazard ratio (HR) = 1.69, 95% confidence interval (CI) (1.09-2.63) and HR = 1.92 (95% CI 1.23-2.94), respectively] and stage III CRC patients treated by surgery alone [HR = 1.39 (95% CI 0.92-2.13) and HR = 1.49 (95% CI 1.02-2.17), respectively]. Low TS, DPD and TP associated with trends for better outcome in stage III patients treated with 5-FU [HR = 0.81 (95% CI 0.49-1.33), HR = 0.70 (95% CI 0.42-1.15) and HR = 0.66 (95% CI 0.39-1.12), respectively].Conclusion Low TS and DPD expression are prognostic for worse outcome in CRC patients treated by surgery alone, whereas low TS, DPD and TP expression are prognostic for better outcome in patients treated with 5-FU chemotherapy. These results provide indirect evidence that low TS, DPD and TP protein expression are predictive of good response to 5-FU chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As the name implies, high expression of DPD mRNA can confer resistance to 5-FU in CRC [9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [10]
In the citing paper
“Studies have shown that the higher expression of TP predicts a good response to 5-FU [9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [10]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [10]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [10]
Citations
Cites
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-5-199503010-00001 · Cited by 925
Salonga, D. S., Danenberg, K. D., Johnson, M. R., Metzger, R., Groshen, S. G., Tsao-Wei, D. D., Lenz, H.-J., Leichman, C. G., Leichman, L., Diasio, R. B., et al. (2000) · PubMed · Cited by 829
Self-citationClinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials
Sargent, D. J., Conley, B. A., Allegra, C., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.112 · Cited by 499
Popat, S., Matakidou, A., & Houlston, R. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.064 · Cited by 449
Beck, A., Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Renée, N., & Milano, G. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00216-r · Cited by 270
Edler, D., Glimelius, B. L. G., Hallström, M., Jakobsen, A. K. M., Johnston, P. G., Magnusson, I., Ragnhammar, P., & Blomgren, H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.039 · Cited by 263
Metzger, R., Danenberg, K. D., Leichman, C. G., Salonga, D. S., Schwartz, E. L., Wadler, S., Lenz, H., Groshen, S. G., Leichman, L., & Danenberg, P. V. (1998) · PubMed · Cited by 259
Elsaleh, H., Powell, B. L., McCaul, K. A., Grieu, F., Grant, R., Joseph, D., & Iacopetta, B. J. (2001) · PubMed · Cited by 204
Self-citationBarratt, P., Seymour, M., Stenning, S., Georgiades, I., Walker, C., Birbeck, K., & Quirke, P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11402-4 · Cited by 194
Etienne, M.-C., Chazal, M., Laurent-Puig, P., Magné, N., Rosty, C., Formento, J.-L., Francoual, M., Formento, P., Renée, N., Chamorey, E., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.091 · Cited by 176
Allegra, C. J., Parr, A. L., Wold, L. E., Mahoney, M. R., Sargent, D. J., Johnston, P., Klein, P., Behan, K., O’Connell, M. J., Levitt, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.080 · Cited by 170
Van Triest, B., Pinedo, H. M., Giaccone, G., & Peters, G. J. (2000) · Annals of Oncology · doi:10.1023/a:1008351221345 · Cited by 169
Ichikawa, W., Uetake, H., Shirota, Y., Yamada, H., Nishi, N., Nihei, Z., Sugihara, K., & Hirayama, R. (2003) · PubMed · Cited by 167
Kornmann, M., Schwabe, W., Sander, S., Kron, M., Sträter, J., Polat, S., Kettner, E., Weiser, H. F., Baumann, W., Schramm, H., et al. (2003) · PubMed · Cited by 157
Graziano, F., & Cascinu, S. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg284 · Cited by 147
van Triest, B., Pinedo, H. M., van Hensbergen, Y., Smid, K., Telleman, F., Schoenmakers, P. S., van der Wilt, C. L., van Laar, J. A. M., Noordhuis, P., Jansen, G., et al. (1999) · PubMed · Cited by 145
Johnston, P. G., Liang, C., Henry, S., Chabner, B. A., & Allegra, C. J. (1991) · PubMed · Cited by 130
Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy.
Diasio, R. B., & Lu, Z. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2239 · Cited by 113
Self-citationAschele, C., Debernardis, D., Tunesi, G., Maley, F., & Sobrero, A. F. (2000) · PubMed · Cited by 109
Johnston, P. G., Benson, A. B., Catalano, P. J., Rao, M. S., O'Dwyer, P. J., & Allegra, C. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.039 · Cited by 90
The Role of Pharmacogenetics and Pharmacogenomics in Cancer Chemotherapy with 5-Fluorouracil
Diasio, R. B., & Johnson, M. R. (2000) · Pharmacology · doi:10.1159/000028401 · Cited by 85
Self-citationTakenoue, T., Nagawa, H., Matsuda, K., Fujii, S., Nita, M. E., Hatano, K., Kitayama, J., Tsuruo, T., & Muto, T. (2000) · Annals of Surgical Oncology · doi:10.1007/bf02523653 · Cited by 81
Popat, S., Chen, Z., Zhao, D., Pan, H., Hearle, N., Chandler, I. R., Shao, Y., Aherne, W., & Houlston, R. S. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl301 · Cited by 69
Westra, J. L., Hollema, H., Schaapveld, M., Platteel, I., Oien, K. A., Keith, W. N., Mauritz, R., Peters, G. J., Buys, C. H. C. M., Hofstra, R. M. W., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi316 · Cited by 58
Aschele, C., Debernardis, D., Bandelloni, R., Cascinu, S., Catalano, V., Giordani, P., Barni, S., Turci, D., Drudi, G., Lonardi, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf327 · Cited by 49
Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients
Chai, S. M., Zeps, N., Shearwood, A.-M., Grieu, F., CHARLES, A. K., Harvey, J., Goldblatt, J., Joseph, D. J., & Iacopetta, B. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00451-3 · Cited by 46
Self-citationAdvances and Challenges in Fluoropyrimidine Pharmacogenomics and Pharmacogenetics
Soong, R., & Diasio, R. B. (2005) · Pharmacogenomics · doi:10.2217/14622416.6.8.835 · Cited by 40
Self-citationAdjuvant chemotherapy for stage II colorectal cancer: the time is right!
Midgley, R. S., & Kerr, R. S. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0228 · Cited by 38
Amatori, F., Paolo, A. D., Tacca, M. D., Fontanini, G., Vannozzi, F., Boldrini, L., Bocci, G., Lastella, M., & Danesi, R. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230410.07899.bc · Cited by 37
Tsuji, T., Sawai, T., Takeshita, H., Nakagoe, T., Hidaka, S., Nanashima, A., Yamaguchi, H., Yasutake, T., Nagayasu, T., & Tagawa, Y. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.09.030 · Cited by 32
Molecular Diagnostics: Assays, Tissues, Progress, and Pitfalls
Allegra, C. J., & Sargent, D. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.073 · Cited by 16
Cited by
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
Tejpar, S., Bertagnolli, M., Bosman, F., Lenz, H.-J., Garraway, L., Waldman, F., Warren, R., Bild, A., Collins-Brennan, D., Hahn, H., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0233 · Cited by 185
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Crea, F., Nobili, S., Paolicchi, E., Perrone, G., Napoli, C., Landini, I., Danesi, R., & Mini, E. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.08.001 · Cited by 137
Metadata
- Authors
- Soong, R., Shah, N., Salto-Tellez, M., Tai, B. C., Soo, R. A., Han, H. C., Ng, S. S., Tan, W. L., Zeps, N., Joseph, D., Diasio, R. B., & Iacopetta, B.
- Affiliations
- National University of Singapore (SG)
- National University Hospital (SG)
- The University of Western Australia (AU)
- University of Alabama at Birmingham (US)
- Corresponding author
- Soong, R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 19
- Issue
- 5
- Pages
- 915-919
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC2931808
- OpenAlex
- W2108707912
- Cited by
- 136
- References
- 36
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 5 · 2019: 6 · 2018: 5 · 2017: 4 · 2016: 3 · 2015: 7 · 2014: 11 · 2013: 12 · 2012: 10
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4239 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- National University of Singapore (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- National Cancer Institute (R01CA116964, CA85381, R01CA085381)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, colorectal cancer, 5-fluorouracil, prognostic factors, chemotherapy response, survival
- MeSH terms
- Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Proteins, Neoplasm Staging, Prognosis, Thymidine Phosphorylase, Thymidylate Synthase, Colorectal Neoplasms, Survival Analysis, Chemotherapy, Adjuvant, Drug Resistance, Neoplasm, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.